Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM326 MAD study in healthy subjects
NCT05171348Phase 1Completed
- Sponsor
- Keymed Biosciences
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CM326 in asthma (5 arms), sponsored by Keymed Biosciences. Primary endpoint: Incidence of adverse events at 24 weeks. Started Jan 2022; status: completed.
02
Drugs
CM326
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05171348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171348.